TIDMFAB

RNS Number : 5440K

Fusion Antibodies PLC

29 August 2023

Fusion Antibodies plc

("Fusion" or the "Company")

Update on AI/ML-Ab(TM) service offering

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has received a first purchase order for its AI/ML-Ab(TM) (pronounced AIM-Lab) services. The customer, based in Australia, was introduced under the framework of the agreement the Company has recently entered into with a leading US-based AI/ML (artificial intelligence and machine learning) company, and the details of this were announced on 21 August 2023. This purchase order demonstrates commercial traction for AI/ML-Ab(TM) and the Directors believe that there is significant market potential for this service offering.

Fusion Antibodies CEO, Adrian Kinkaid said : "We are delighted to be able to announce the first order for our AI/ML-Ab(TM) service offering. This confirms that we are pursuing the right strategy at Fusion and that the market values the services we offer. As our industry rapidly evolves to find new ways to hasten the discovery of better bio-therapeutics to take to the clinic, Fusion is well positioned at the forefront of Antibody discovery and development processes, including those using AI/ML, and with all the resources required to meet the growing need for our services."

Enquiries:

 
 Fusion Antibodies plc                                   www.fusionantibodies.com 
 Adrian Kinkaid, Chief Executive Officer                          Via Walbrook PR 
  Richard Buick, Chief Scientific Officer 
 
 Allenby Capital Limited                                      Tel: +44 (0)20 3328 
                                                                             5656 
 James Reeve/Vivek Bhardwaj (Corporate 
  Finance) 
  Tony Quirke/Joscelin Pinnington (Sales 
  and Corporate Broking) 
 
 Walbrook PR                  Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                                 Mob: +44 (0)7876 741 
                                                                              001

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx (TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSEEFLAEDSESA

(END) Dow Jones Newswires

August 29, 2023 02:00 ET (06:00 GMT)

Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Fusion Antibodies Charts.
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Fusion Antibodies Charts.